MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by CureVac

News headline image
CureVac Files Patent Infringement Lawsuit in Germany Against BioNTech
From CureVac
Via AccessWire
Topics Intellectual Property Lawsuit
Tickers CVAC
News headline image
CureVac Announces Voting Results of General Meeting
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac Announces Changes of CDO - Myriam Mendila to Succeed Klaus Edvardsen
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development
From CureVac
Via AccessWire
Tickers CVAC
News headline image
Curevac Announces Financial Results For The First Quarter Of 2022 And Provides Business Update
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac and GSK Enter into Pandemic Preparedness Contract with German Government
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R)
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry
From CureVac
Via AccessWire
Tickers CVAC
News headline image
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update
From CureVac
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Streamlines European Network for mRNA Product Manufacturing
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic
From CureVac
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Announces Financial Results for the Second Quarter and First Half of 2021 and Provides Business Update
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Announces Appointment of Dr. Malte Greune as Chief Operating Officer and Transition of Dr. Florian von der Mülbe to Lead Accelerated Development of The RNA Printer(R)
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Announces Voting Results of General Meeting
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Provides Supervisory Board Update
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac Appoints Klaus Edvardsen as Chief Development Officer
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
News headline image
CureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Tickers CVAC
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story